Carcinoembryonic antigen (CEA) preparations, from various sources were compared by radioimmunoassay. The preparations studied included four CEA standards (CEA-Roche, CEA-Montreal, CEA-City of Hope, and CEA-British) and CEA from serum and liver metastases of a patient with cancer of the colon who had an extremely high concentration of serum CEA (more than 26,000 ng/ml). The data indicate that the CEA-Roche standard differs significantly from the other three CEA standards tested, and that the serum CEA from the patient was antigenically different from currently available CEA standards as well as from the CEA obtained from the patient's own liver metastases. These antigenic differences were reflected in radioimmunoassay inhibition curves that were different and that were not affected by perchloric acid extraction of CEA. Because of the antigenic variation in the serum CEA, markedly different CEA concentrations (varying by three orders of magnitude) were measurable by two different antisera (Roche and Montreal). All the various CEA standards and samples cochromatographed on columns of Sepharose-6B, despite the large antigenic variation.
After the demonstration of a tumor-specific antigen (carcinoembryonic antigen, CEA) in adenocarcinomas of the gastrointestinal tract by Gold and Freedman (1) , it was shown that immunoreactive CEA was present in the plasma of almost all patients with colon carcinoma. This suggested that serologic measurement of this antigen could be a useful diagnostic test for this malignancy (2) . However, the availability of a well characterized CEA standard is an important prerequisite for a valid, generally applicable CEA assay.
Coligan et al. (3) isolated CEA from several gastrointestinal tumors and found that their CEA preparation (CEA-City of Hope) was immunologically indistinguishable from CEA prepared by Gold and Freedman (CEA-Montreal) (4) . The "First British CEA Standard" (CEA-British) was prepared from liver metastases arising from colon carcinoma by methods similar to those used by Gold and Freedman (4) and Coligan et al. (3) , and was found (by the National Institute of Biological Standards and Control, London) to be similar to the CEA-Montreal and CEA-City of Hope by immunodiffusion and polyacrylamide gel electrophoresis, as well as in amino-acid and carbohydrate composition. Hoffmann-LaRoche (Nutley, N.J.) prepared their own CEA (CEA-Roche) and developed a standardized method and kit for routine clinical assays (5, 6) . Although studies in which both Roche and Montreal reagents were used showed a high degree of correlation of positive CEA tests in sera from cancer patients (7, 8) ,' a comparative immunochemical analysis of all four standards has not been reported.
We previously observed marked variation (of more than two orders of magnitude) in the assay of CEA in sera of some cancer patients when two different anti-CEA antisera were used (9, 10) . This antigenically different serum CEA was demonstrable in all sera tested which contained very high levels (more than 500 ng/ml) of CEA, as measured by Roche reagents (9, 10 1A shows that RIA inhibition curves were similar with City of Hope, Montreal, and British CEA standards when Roche anti-CEA was used, whereas the inhibition curve of the CEA-Roche standard was clearly different. When three of the CEA standards were tested by the identical RIA method but with Montreal instead of Roche anti-CEA (see Fig. 2A (Fig. 2B) . Furthermore, the addition of 6.25 ng of CEA-Roche resulted in significant additional inhibition in the presence of from 0.4 to 40.0 ,l of serum R. K., which contained between 10.5 and 1,050 ng of CEA when assayed with the Roche CEA kit. These results indicate that this antiserum reacted with antigenic determinants on the serum CEA which are distinctly different from the CEA-Roche standard.
The addition of increasing amounts of normal serum (up to 50 ,l) did not significantly inhibit in the radioimmunoassay (Fig. 2C) . Furthermore, the identical inhibition caused by 6.25 ng of CEA-Roche, when added to increasing aliquots of normal serum (Fig. 2G) , demonstrates a lack of inhibition by normal serum in these aliquots when the "direct" CEA radioimmunoassay was used. Effect of perchloric acid extraction upon serum CEA Serum R. K. was extracted with dilute perchloric acid (2) . The resultant supernatant was dialyzed against large volumes of distilled water and lyophilized, and the residue reconstituted to the original serum volume with 0.9% NaCI. Increasing aliquots of this perchloric acid extract results in increasing inhibition to a maximum greater than that seen with unextracted serum under the same conditions with the same reagents (Fig. SA) . However, the addition of 6.25 ng of CEA-Roche still produced significant additional inhibition in the presence of from 0.1 to 40 Ml of this cancer serum extract (Fig. SB) . Thus, the antigenic difference between serum CEA and the CEA-Roche noted in Fig. 2B was not abolished or significantly altered by perchloric acid extraction. This observation is of importance because all presently available CEA standards are prepared from perchloric acid extracts of tumors.
Differences between serum and liver CEA CEA standards and antigen preparations used for raising anti-CEA antisera are usually prepared from liver metastases (1) (2) (3) (4) (5) . Therefore, we compared the CEA in the serum of this patient to the CEA extracted from his own liver metastases. Increasing amounts of the liver metastases extract resulted in increasing inhibition until a maximum of 65% was reached when Montreal antisera was used (see Fig. 4B ). The slope. and maximum inhibition caused by the liver extract was distinctly different from either Roche or Montreal standards shown in Fig. 4A . Furthermore, the addition of 6.25 ng of CEA-Roche resulted in no additional detectable inhibition when it was added to 10 JAI or more of the tissue extract. The convergence of the inhibition curves when CEA was added to the tissue extract indicates that the tissue CEA may share some antigenic determinants with the CEARoche standard that it does not share with the antigenically different CEA circulating in the same patient's serum (see Figs. 2B and SB) .
The results of gel filtration of the various CEA preparations are shown in Fig. 5 . CEA in the tumor extract, whole serum, and perchloric acid extracted serum all cochromatographed with iodinated CEA-Roche. In additional experiments we noted that CEA-Montreal also cochromatographed with 125I-labeled CEA-Roche.
DISCUSSION
Our data demonstrate that CEA-Roche, which is currently used extensively in clinical laboratories for CEA assays, was different from the other three CEA standards tested in this study (CEA-Montreal, CEA-City of Hope, and' CEA-flritish). Under the conditions of the radioimmunoassay msed, the latter three standards resulted in very similar inhibition curves, but all three were clearly different from CEA-Roche when either Montreal or Roche anti-CEA antisera was used.
Furthermore, a serum CEA was shown to be immunologically different from all four CEA standards; this has important implications for CEA assays. The difference between the inhibition curves of the standards and the early plateau of maximum inhibition seen in a serum CEA, when Montreal anti-CEA was used, resulted in a calculated CEA concentration which varied with the amount assayed. For example, by RIA (Fig. 2B) . Based on simultaneously prepared standard curves (Fig. 2A) , the serum was calculated to contain 8 ng of CEA/,Ml when CEA-Roche was used as the standard, and 130 or 168 ng of CEA/Mul, respectively, when Montreal or British CEA standards was used. In addition, the shape of the inhibition curve of the serum CEA assayed directly (i.e., without prior perchloric acid extraction) differed from that of the standards and was nonlinear. When the amount of the serum analyzed was increased, the final calculated concentration (expressed as ng of CEA/ml of serum) decreased. If a perchloric acid extract from 5 ml of. this serum were to be used in this RIA, as originally suggested by Thomson et al. (2) , the calculated CEA concentration would yield a value of less than 50 ng/ml, in contrast to the value of more than 25,000 ng/ml obtained with the Roche assay kit. Therefore, the calculated serum CEA concentration can vary by three orders of magnitude depending on the CEA standard used, the amount of serum actually tested, and the particular anti-CEA antiserum used in RIA.
CEA can be separated into multiple molecular forms, by ion exchange chromatography and isoelectric focusing (12) (13) (14) . These forms with different net charges contained a similar amino-acid composition and apparently differed only in carbohydrate content. However, the different CEA forms were said to be antigenically identical by Ouchterlony diffusion (12) . Our results with radioimmunoassay suggest that CEA must contain a number of different antigenic determinants.
Normal crossreacting glycoproteins such as NCA (normal colon antigen) described,by von Kleist and others (15) , cannot explain our results. The serum CEA was similar in molecular weight to the CEA standards. Furthermore, the Montreal antiserum was heavily absorbed with perchloric acid extracts of normal lung, liver, colon, and plasma, as described by Thomson et al. (2) .
To explain the results of our experiment, we must assume that CEA is a family of "isoantigens" which have multiple antigenic determinants. Some of these antigenic determinants may be common to all the isoantigens, whereas others may be antigenically distinct by RIA. Furthermore, different anti-CEA antisera may consist of antibody species that recognize different CEA determinants on the different CEA isoantigens. Thus, the results of radioimmunoassay may only reflect the binding affinity of polyvalent anti-CEA antibodies to a mixture of different CEA isoantigens.
Attempts to determine the chemical nature of the immunodominant antigenic determinants of CEA have so far been inconclusive (16) (17) (18) (19) (20) (21) . Blood group A and nonspecific crossreacting antigens such as NCA may share one or more antigenic determinants with CEA, but are chemically distinguishable from CEA (15) . Our experiments suggest that there are a number of CEA isoantigens not recognizable by some presently available anti-CEA antisera which are presumed to be monospecific. The concept of multiple CEA isoantigens may explain why the sera of many patients with nonmalignant conditions (e.g., chronic inflammatory bowel disease without cancer) contain immunoreactive substances which mimic CEA by radioimmunoassay (22) .
The recent isolation of CEA-S, a fraction separated from a purified CEA preparation, but antigenically distinguishable from CEA (23, 24) , is also consistent with the assumption that CEA is a family of isoantigens. Production of antisera with restricted specificity to the different CEA isoantigens appears to offer a new approach for the detection of a more tumor-specific form of CEA and a more reliable serologic diagnosis of malignancy.
